Myc Expression News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Myc expression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Myc Expression Today - Breaking & Trending Today

Dr Vincelette on MYC Expression in Myelofibrosis

Nicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms. ....

Nicoled Vincelette , Moffitt Cancer Center , Myc Expression , Triple Negative Myeloproliferative Neoplasms ,

Phase 1 Trial Set to Explore Efficacy and Safety of KB-0742 in Solid Tumors

Brian Van Tine, MD, PhD, discusses key considerations for understanding the biology of MYC, the rationale for the phase 1 study of KB-0742 in MYC-amplified or -overexpressed relapsed or refractory solid tumors, and patient characteristics that may signal their eligibility for participation in this trial.

....

United States , Washington University , Division Of Oncology , Brian Van Tine , Van Tine , Medical Oncology , Washington University School , Patients With Relapsed Refractory Lymphoma Or Solid Tumors , Breast Cancer , Ovarian Cancer , Lung Cancer , Myc Expression , Kb 0742 ,

Novel CDK9 Inhibitor Under Investigation in Solid Tumors and NHL

Miguel Villalona-Calero, MD, discusses the unique mechanism of action of KB-0742 and the rationale and design of a phase 1 trial investigating the safety and efficacy of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma. ....

United States , Miguel Villalona Calero , Early Phase Therapeutics Program , Developmental Cancer Therapeutics Program , Medical Oncology , Therapeutics Research , Kb 0742 , Patients With Relapsed Refractory Lymphoma Or Solid Tumors , Breast Cancer , Ovarian Cancer , Lung Cancer , Myc Expression , Non Hodgkin Lymphoma , City Of Hope ,

Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech's website

Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the ....

Bruxelles Capitale , United States , University Hospital , Hans Kolam , Vrije Universiteit , Vrije University , University Hospital Dresden , Active Biotech , Targets Immunosuppressive Myeloid Cells , Increases Osteogenesis , Has Direct Anti Myeloma Effects , Myc Expression , Vivo Poster , Plasma Cell Dyscrasias , Inflammatory Niche , Tasquinimod Restores Hematopoietic Support , Suppresses Immune Checkpoint Expression ,

Active Biotech: New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)

Lund, November 4, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for presentation ....

United States , University Hospital , Bruxelles Capitale , Hans Kolam , Vrije University , University Hospital Dresden , Active Biotech , Targets Immunosuppressive Myeloid Cells , Increases Osteogenesis , Has Direct Anti Myeloma Effects , Myc Expression , Plasma Cell Dyscrasias , Inflammatory Niche , Tasquinimod Restores Hematopoietic Support , Suppresses Immune Checkpoint Expression , Central European Time ,